Skip to main content
KalVista Pharmaceuticals, Inc logo
Menu toggle

Main navigation

  • About KalVista
    • Senior Management
    • Board of Directors
    • Contact Us
    • Careers
  • Products & Pipeline
    • Pipeline
    • KalVista for HAE
    • KalVista for DME
    • Publications
  • For Patients
    • HAE Resources
    • KVD900 for HAE
    • DME Resources
  • For Healthcare Providers
    • HAE Resources
    • KVD900 for HAE
    • DME Resources
    • Publications
    • Expanded Access
  • For Investors
    • Stock Information
    • News Releases
    • Events Calendar
    • Presentations
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance

KalVista Pharmaceuticals
creating a new generation of small molecule protease inhibitors for HAE and DME

Hereditary Angioedema (HAE)

Diabetic Macular Edema (DME)

News

Kalvista Pharmaceuticals

KalVista Pharmaceuticals Reports Phase 2 Clinical Trial Results in Patients with Diabetic Macular Edema

Dec 9, 2019
Kalvista Pharmaceuticals

KalVista Pharmaceuticals Reports Fiscal Second Quarter Results

Dec 3, 2019
Kalvista Pharmaceuticals

KalVista Pharmaceuticals Provides Business Update

Nov 13, 2019
All News
  • Print Page
  • Email Alerts
  • RSS
  • Search

Footer

  • About KalVista
  • Products & Pipeline
  • For Patients
  • For Healthcare Providers
  • For Investors
  • Contact Us
+1 (857) 999 0075 info@kalvista.com

Social Menu

  • Linked In
  • Twitter
Copyright © 2019 | All rights reserved.

Footer Bottom

  • KalVista Terms
  • Privacy
`